Product Overview
【Generic name】
Tamsulosin hydrochloride sustained-release capsules
【Drug name】
Shunshuangan Tamsulosin hydrochloride sustained-release capsules
【Main ingredients】
The main ingredient of this product is tamsulosin hydrochloride.
【Functions and indications】
Urinary disorders caused by prostatic hyperplasia.
【Usage and dosage】
Adults once a day, one capsule each time (0.2mg), take after meals. It can be increased or decreased appropriately according to age and symptoms.
【Adverse reactions】
1. Serious adverse reactions: absence, loss of consciousness (frequency unknown): Because there may be transient loss of consciousness accompanied by a drop in blood pressure, the medication process should be fully observed. If abnormal conditions occur, the medication should be discontinued and appropriate treatment measures should be taken. 2. Other adverse reactions: ① Mental and nervous system: occasionally dizziness, headache, staggering and other symptoms. ② Circulatory system: occasionally blood pressure drop, postural hypotension, increased heart rate, palpitations, etc. ③ Allergic reaction: Occasionally itching, rash, and urticaria may occur. If such symptoms occur, the medication should be stopped. ④ Digestive system: Occasionally nausea, vomiting, stomach discomfort, abdominal pain, loss of appetite, diarrhea, constipation, dysphagia, etc. ⑤ Liver function: Occasionally GOT, GPT, and LDH increase. ⑥ Intraoperative Floppy Iris Syndrome: It has been reported that patients who are taking or have taken a1 receptor antagonists have experienced intraoperative Floppy Iris Syndrome (Intraoperative Floppy Iris Syndrome) due to a1 receptor antagonism. Ophthalmologists should pay attention to the occurrence of intraoperative Floppy Iris Syndrome when performing ophthalmic surgery. ⑦ Others: Occasionally nasal congestion, epistaxis, edema, fatigue, priapism, ejaculation disorders, blurred vision, visual impairment, erythema multiforme, exfoliative dermatitis, etc. Expand
【Precautions】
1. This product can be used after excluding the diagnosis of prostate cancer. Because this product has the effect of relieving symptoms, it is recommended that patients be screened for other diseases that can cause the same symptoms as prostate hyperplasia, such as prostate cancer, before using tamsulosin for treatment, and screened regularly after tamsulosin treatment. 2. Pay close attention to changes in blood pressure when taking antihypertensive drugs in combination. 3. Be careful not to chew the granules in the capsule. 4. Use with caution in patients with postural hypotension and severe liver dysfunction. 5. No dose reduction is required for patients with renal insufficiency. Since it has not been studied in patients with severe renal dysfunction (creatinine clearance < 10ml/min), such patients should use it with caution. 6. Because dizziness may occur, please be careful when engaging in dangerous work such as high-altitude work and car driving. 7. When tamsulosin is used in combination with strong inhibitors of CYP3A4 or CYP2D6 (e.g. ketoconazole, paroxetine), the exposure of tamsulosin may increase significantly. When used in combination with ketoconazole (CYP3A4 inhibitor), the Cmax and AUC of tamsulosin will increase by 2.2 and 12.8 times, respectively. When used in combination with paroxetine (CYP2D6 inhibitor), the Cmax and AUC of tamsulosin will increase by 1.3 and 1.6 times, respectively. 8. There are reports of patients with a history of sulfonamide overdose experiencing allergic reactions when taking tamsulosin. Patients with a history of allergy to sulfonamides should be cautious when taking tamsulosin hydrochloride. Expand
[Interactions]
1. The combination of this product with other adrenergic blockers may affect its pharmacokinetics and pharmacodynamics. It is recommended not to use the two together. 2. Cimetidine increases the absorption of this product and reduces its clearance. Be cautious when used in combination, especially when the dose of this product exceeds 0.4mg.
[Specification]
10 tablets/box
[Approval number]
National Medicine Standard H20203426
[Manufacturer]
Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
